Treace Medical Concepts (TMCI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
19 May, 2026Opening remarks and agenda
Meeting held virtually to increase inclusivity and reach more stockholders.
Business portion conducted first, followed by a Q&A session.
Introduction of board members and independent auditors present.
Corporate Secretary designated to handle procedural matters.
Board and executive committee updates
Board members present included John Bakewell, Jane Kiernan, Betsy Hanna, and Lance Berry.
Shareholder proposals
Election of directors for terms expiring at the 2029 annual meeting.
Advisory non-binding vote on executive compensation.
Ratification of Grant Thornton LLP as independent auditors for 2026.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Treace Medical Concepts
- Q2 2026 revenue fell 4–4.2% YoY, with improved net loss and raised guidance amid new product adoption.TMCI
Q2 2026 - Accelerated growth, improved financials, and new technologies drive expanding market leadership.TMCI
Sidoti Small-Cap Virtual Investor Conference - Q1 2026 revenue fell 10.2% to $47.2M, with net loss at $18.0M and guidance reaffirmed.TMCI
Q1 2026 - 2026 proxy covers director elections, say-on-pay, auditor ratification, and key governance updates.TMCI
Proxy filing - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.TMCI
Proxy filing - 2026 revenue is guided flat to -6%, with Q4 growth expected from new product launches.TMCI
Q4 2025 - Q3 revenue up 11% to $45.1M, guidance raised, and new products plus litigation drive growth.TMCI
Q3 2024 - Q2 revenue up 6% to $44.5M; net loss widens, but 2024 growth and margin outlook reaffirmed.TMCI
Q2 2024 - Two new MIS osteotomy platforms launch in late 2024, expanding reach amid rising competition.TMCI
2024 Truist Securities MedTech Conference